- Qorvo ( NASDAQ: QRVO ) announced on Thursday that the FDA granted the emergency use authorization (EUA) for Qorvo Omnia SARS-CoV-2 Antigen Test for use in Point-of-Care (POC) settings.
- The test will be authorized to detect viral antigens qualitatively based on nasal swab specimens.
- According to the company, the test is indicated both for those with symptoms and those without symptoms or other epidemiological reasons to suspect COVID-19.
- In April 2021, the FDA first issued a EUA for the test limiting its use in laboratories. The latest authorization expands its availability for more locations such as doctor's officers, urgent care centers, and retail pharmacies.
- "As the COVID testing market transitions to an endemic state and the increase in the omicron variant drives lower viral load, high quality rapid testing infrastructure is needed in POC settings," noted Erik Allen, who serves as president of Qorvo unit, Qorvo Biotechnologies.
- Read: Qorvo ( QRVO ) beat Street forecasts with its 1Q financials for fiscal 2023.
For further details see:
Qorvo wins FDA nod for COVID-19 rapid antigen test in POC settings